Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs

doi:10.12092/j.issn.1009-2501.2019.02.009

Abstract

Abstract:

AIM: To evaluate the association between IGF-1 genetic polymorphisms and blood pressure response to antihypertensive drugs. METHODS:A case-sectional study of 780 hypertension patients taking compound reserpine, Jiang Ya Tablet and Zhenju Jiang Ya Tablet were recruited.Five tagging single nucleotide polymorphisms of IGF-1 gene (rs5742612, rs35767, rs6214, rs6218, rs6219) were selected, and the genotyping was performed by TaqMan technique. A quantitative trait analysis and stratification analysis were performed for evaluating the relation between IGF-1genetic variation and blood pressure by taking different antihypertensive drugs. RESULTS:Quantitative trait analysis showed that there were significant differences in diastolic blood pressure (DBP) among the genotypes(GG,GA and AA) of rs6219 in hypertensive taking Jiang Ya Tablet after adjusting the covariant (P=0.01). In hypertensive taking compound reserpine, rs5742612 T/C and rs6218 T/C were significantly associated with systolic blood pressure（SBP）after adjustment for covariates, P values of 0.04 and 0.017, respectively. In hypertensive taking Zhenju Jiang Ya Table, after adjusting the covariant, the variation of rs6218 significantly related to DBP, and the variation of rs6219 was associated with SBP(The P values were 0.017 and 0.033, respectively).Further stratification analysis indicated that in female hypertensive taking Jiang Ya Tablet, SBP significantly decreased with the variation (T>C) of rs37567 (P=0.028). Interestingly, in male hypertensive taking Jiang Ya Tablet, DBP significantly increased with the variation of rs37567 (P=0.038). CONCLUSION: IGF-1 gene polymorphism is significantly related to efficacy of antihypertensive drugs including compound reserpine, Jiang Ya Tablet and Zhenju Jiang Ya Tablet, and may serve as a useful biomarker for the treatment of hypertension and gene therapy.

Key words: insulin-like growth factor (IGF)-1, gene polymorphisms, antihypertensive drugs, blood pressure

CLC Number:

R544

CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui. Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.

References

［1］Lee DS, Massaro JM,Wang TJ,et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life［J］.Hypertension, 2007,50(5):869-876.
［2］王京娥,陈燕,高山,等.IGF-1、HMGB-1、GSN和MIF水平在高血压脑出血中的意义［J］.河北医药,2016,38(18):2733-2736.
［3］Schutte AE,Volpe M,Tocci G,et al.Revisiting the relationship between blood pressure and insulin-like growth factor-1［J］. Hypertension, 2014,63(5):1070-1077.
［4］Higashi Y,Quevedo HC,Tiwari S,et al.Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging［J］. Front Horm Res,2014, 43:107-124.
［5］Cannata D,Vijayakumar A,Fierz Y,et al.The GH/IGF-1 axis in growth and development: new insights derived from animal models［J］. Adv Pediatr,2010,57(1):331-351.
［6］张丽,马雪,王俭勤.IGF系统与糖尿病肾病关系的研究进展［J］.中国中西医结合肾病杂志,2017,18(3):274-277.
［7］Delafontaine P,Song YH,Li Y.Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels［J］. Arterioscler Thromb Vasc Biol,2004, 24(3):435-444.
［8］Koegelenberg AS,Schutte R,Smith W,et al.Bioavailable IGF-1 and its relationship with endothelial damage in a bi-ethnic population: The SABPA study［J］.Thrombosis research,2015,136(5):1007-1012.
［9］Andreassen M,Raymond I,Kistorp C,et al.IGF-1 as predictor of all cause mortality and cardiovascular disease in an elderly population［J］. Eur J Endocrinol,2009, 160(1):25-31.
［10］Schutte AE,Schutte R,Smith W,et al.Compromised bioavailable IGF-1 of black men relates favourably to ambulatory blood pressure: The SABPA study［J］.Atherosclerosis,2014,233(1):139-144.
［11］王斌,向睿.血清炎性因子及胰岛素样生长因子相关指标与妊娠期高血压疾病的相关性研究［J］.海南医学院学报,2017,23(5):698-700.
［12］Yang HC,Liang YJ,Chen JW,et al.Identification of IGF1, SLC4A4, WWOX, and SFMBT1 as hypertension susceptibility genes in Han Chinese with a genome-wide gene-based association study［J］. PloS one,2012,7(3):e32907.
［13］Aoi N,Nakayama T,Soma M,et al.The insulin-like growth factor-1 gene is associated with cerebral infarction in Japanese subjects［J］.Hereditas,2012,149(5):153-162.
［14］Sesti G,Mannino GC,Andreozzi F,et al.A polymorphism at IGF1 locus is associated with carotid intima media thickness and endothelium-dependent vasodilatation［J］. Atherosclerosis,2014,232(1):25-30.
［15］韩胜红.GH-IGF-I轴基因多态性及环境因素与缺血性脑卒中的分子流行病学研究［D］.博士,华中科技大学,2009.
［16］Lin HL,Ueng KC,Wang HL,et al. The impact of IGF-1 gene polymorphisms on coronary artery disease susceptibility［J］. J Clin Lab Anal,2013,27(2):162-169.
［17］苏琼华,郭海鸥.基于药物基因组学的高血压个体化用药分析［J］.中华高血压杂志, 2013,21(11):1019-1022.
［18］唐强,刘海玲,刘昭前.抗高血压药物的基因组学研究进展［J］.中南药学,2007,5(2): 157-160.
［19］郭道遐,陈燕春,王林红,等.高迁移率族蛋白1基因多态性与中国南方农村常用高血压药物疗效的关系［J］.中国临床药理学与治疗学,2014,19(7): 766-771.
［20］金岳龙,王林红,朱丽君,等.一氧化氮合酶基因多态性与常用降压药疗效的关联研究［J］.中国临床药理学与治疗学,2017,22(5):538-544.

[1]	JIN Yuelong, WANG Linhong, ZHU Lijun, LIANG Wei, DUAN Ying, YANG Song, CHEN Yanchun, ZHAO Xianghai, SHEN Chong, YAO Yingshui. Association study of NOS3 genetic polymorphism and the efficacy of anti-hypertensive drug treatment on patient with essential hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 538-544.
[2]	CHEN Tao, YAN Yongxing, SHEN Yonghui. Application of serum B type natriuretic peptide precursor and blood pressure variability in patients with non-cardiogenic ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 570-573.
[3]	GUO Yu, ZHOU Hong-hao, LIU Zhao-qian. MiRNA and interindividual difference in drug response [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 443-448.
[4]	CHEN Yong-fei, SHAO Hua, YU Feng. Research progress of glucagon-like peptide-1 and analogues on blood pressure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 228-233.
[5]	HUANG Yao-hua, TANG Xin-ran, WANG Yang, ZHAO Yan-yan, LI Wei. Application of SAS procedures in evaluation of trough／peak ratio in ambulatory blood pressure monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1246-1250.
[6]	YIN Fang, LI Yun-fei, HUANG Ji-han, LI Lu-jin, ZHENG Qing-shan. A example introduce: clinical design and quantitative evaluation of ambulatory blood pressure monitoring for once daily antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 666-671.
[7]	SUN Xiao-lei, GUAN Jun, YU Zhong-xiang, WANG Shao-hua, YAN Mei-xing, LIU Hua-qiang. Effects of bisoprolol with different drug administration time on the blood pressure of non-dippers hypretension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 292-296.
[8]	MI Qing-xian, ZHANG Ming-sheng. Hypotensive effect and its mechanism of taurine in fructose-induced hypertension rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(2): 160-164.
[9]	DING Zheng, DENG Jie, SONG Hong-tao. Advances in the influence of MDR1 gene polymorphisms on pharmacokinetics of related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1191-1196.
[10]	XU Lin-yong, ZHANG Wei, ZENG Fang, FU Chen-chao, ZHAO Li, ZHAO Xiao-hua, SUN Zhen-qiu. Auto statistical report for trough/peak ratio index in the evaluation of ambulatory blood pressure monitoring by SAS software [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 798-802.
[11]	FENG Yu, YANG Lin, DAI De-zai, ZHANG Can, DAI Yin. Comparison of inhibitory effects of CPU-86017 and its optical derivates on mouse blood pressure and rat aortic contraction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 23-27.
[12]	LIU Xiao-yu, WU Dang-fang, ZHOU Yan, LI Jie, ZHANG Yan-hai. Change of decreasing blood pressure on pain threshold of spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 474-476.
[13]	JIANG De-chun, BAI Xiang-rong, WANG Yu-qin, LI Lin. Advances in studies on population pharmacokinetics of antiepileptic drugs and CYP450 gene polymorphisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(11): 1207-1212.
[14]	CAI Ping, HONG Hua-shan, WANG Yi-bo. Relationship between different level of blood pressure and incidence of cerebral complication in patients with essential hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1030-1032.
[15]	SUI Yu-xia, SUN An-sheng, YU Li-mei, WU Qin, HUANG Xie-nan, SHI Jing-shan, YUAN Mu. Effects of naftopidil's ramification-BWYJ on blood pressure in rat and haemodynamics in cats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(8): 852-856.